Indeed, although a major debate is still ongoing with regard to the optimal ER expression threshold for defining the access to endocrine therapy32 a mounting body of evidence suggests that patients harboring ER levels ranging from 1 to 10% (the so-called ER-low breast cancer) are phenotypically more similar to TN than HR-positive breast cancer33–36. This evidence concerns the gene ESR1 and breast cancer.